



Universiteit  
Leiden  
The Netherlands

## **The Lambert-Eaton myasthenic syndrome**

Wirtz, P.W.

### **Citation**

Wirtz, P. W. (2005, November 7). *The Lambert-Eaton myasthenic syndrome*. Febodruk B.V.  
Retrieved from <https://hdl.handle.net/1887/4275>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4275>

**Note:** To cite this publication please use the final published version (if applicable).

# The Lambert-Eaton myasthenic syndrome

*Clinical, epidemiological and immunological studies*

Paul W. Wirtz

*Cover photograph:* Shells of the marine snails *Conus magus* and *Conus geographus*, which prey on fish by injecting  $\omega$ -conotoxins. These toxins block P/Q-type and N-type voltage-gated calcium channels.

Printing: Febodruk B.V.

ISBN-10: 90-9019914-4

ISBN-13: 9789090199146

© P.W. Wirtz, 2005

# The Lambert-Eaton myasthenic syndrome

*Clinical, epidemiological and immunological studies*

## **Proefschrift**

ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van de Rector Magnificus Dr. D.D. Breimer,  
hoogleraar in de faculteit der Wiskunde en  
Natuurwetenschappen en die der Geneeskunde,  
volgens besluit van het College voor Promoties  
te verdedigen op maandag 7 november 2005  
klokke 15.15 uur

door

**Paul Willem Wirtz**  
geboren te Utrecht in 1971

## **Promotiecommissie**

### **Promotor:**

Prof.dr. A.R. Wintzen

### **Co-promotor:**

Dr. J.J.G.M. Verschuuren

### **Referent:**

Prof.dr. J.H. Wokke (Universiteit Utrecht)

### **Overige leden:**

Prof.dr. J.B. Kuks (Rijksuniversiteit Groningen)

Dr. B.O. Roep

This research project was supported by a grant of the Prinses Beatrix Fonds (project-number 97-0213).

## Contents

### Introduction

1. Introduction and aims 7

### The epidemiology of the Lambert-Eaton myasthenic syndrome

2. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland (*J Neurol* 2003;250:698-701) 21
3. The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands (*Neurology* 2004;63:397-398) 31

### Clinical characteristics of LEMS

4. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome (*J Neurol Neurosurg Psychiatry* 2002;73:766-768) 37
5. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases (*Clin Neurol Neurosurg* 2002;104:359-363) 45
6. The Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer (*Muscle & Nerve* 2005;32:226-229) 57
7. Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families (*J Neurol* 2004;251:1255-1259) 65

### Immunopathogenesis of LEMS

8. HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumour (*Hum Immunol* 2001;62:809-813) 77
9. High innate production of interleukin-10 and tumour necrosis factor- $\alpha$  contributes to susceptibility for non-paraneoplastic Lambert-Eaton myasthenic syndrome (*J Neuroimmunol* 2003;140:194-197) 87
10. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome (*J Neuroimmunol* 2005;159:230-237) 97
11. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer (*J Neuroimmunol* 2005;164:161-165) 115

**Therapy of LEMS**

12. Efficacy of 3,4-diaminopyridine and pyridostigmine in the Lambert-Eaton myasthenic syndrome	125
---	-----

**Conclusions**

13. Summary and conclusions	137
-----------------------------	-----

Nederlandse samenvatting en conclusies	147
--	-----

Curriculum Vitae	155
------------------	-----

List of publications	157
----------------------	-----